Pharmacovigilance study for a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form

ELSEVIER DOYMA SL

Lugar: Madrid; Año: 2006 vol. 34 p. 242 - 242

p style="LINE-HEIGHT: normal; TEXT-INDENT: 0cm; MARGIN: 0cm 0cm 6pt 1cm" class="MsoNormal">Introduction: Intravenous immunoglobulin (IVIG) therapy is an effective treatment in patients with different diseases. This product must comply with all the regulatory requirements reestablished by the World Health Organization and the European Pharmacopoeia for clinical tolerance, therapeutic efficacy, and viral safety. Although IVIG are effective and safe products, in same patients they may cause adverse reactions.